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Galectins have emerged as a novel family of immuno-
regulatory proteins implicated in T cell homeostasis.
Recent studies showed that galectin-1 (Gal-1) plays a
key role in tumor-immune escape by killing antitumor
effector T cells. Here we found that Gal-1 sensitizes hu-
man resting T cells to Fas (CD95)/caspase-8-mediated
cell death. Furthermore, this protein triggers an apo-
ptotic program involving an increase of mitochondrial
membrane potential and participation of the ceramide
pathway. In addition, Gal-1 induces mitochondrial coa-
lescence, budding, and fission accompanied by an in-
crease and/or redistribution of fission-associated mole-
cules h-Fis and DRP-1. Importantly, these changes are
detected in both resting and activated human T cells,
suggesting that Gal-1-induced cell death might become
an excellent model to analyze the morphogenetic
changes of mitochondria during the execution of cell
death. This is the first association among Gal-1, Fas/Fas
ligand-mediated cell death, and the mitochondrial path-
way, providing a rational basis for the immunoregula-
tory properties of Gal-1 in experimental models of
chronic inflammation and cancer.
Galectins, a growing family of carbohydrate-binding pro-
teins, have recently attracted considerable attention as novel
regulators of immune cell homeostasis (1–3). Despite extensive
sequence homology and similar carbohydrate specificity, vari-
ous members of this protein family behave as amplifiers of
inflammatory response, whereas others activate homeostatic
signals that serve to shut off immune effector functions (1–3).
Recently, it has become clear that galectin-1 (Gal-1),1 a mem-
ber of this protein family, has the potential to impair T cell
effector functions by antagonizing T cell activation (4), promot-
ing growth arrest (5), and/or blocking proinflammatory cyto-
kine secretion (6–8). Moreover, Gal-1 presented by the extra-
cellular matrix promotes apoptosis of activated T cells in a
carbohydrate-dependent manner, thus contributing to the es-
tablishment of immune cell tolerance (9–11). Interestingly,
susceptibility to Gal-1-induced apoptosis is modulated by the
regulated expression of specific glycosyltransferases (12, 13).
Therapeutic administration of recombinant Gal-1 or its genetic
delivery suppresses chronic inflammatory disorders by modu-
lating T cell apoptosis in vivo (6, 8). In addition, we have
recently demonstrated that Gal-1 contributes to the immune
privilege of tumors by killing anti-tumor CD4 and CD8
effector T lymphocytes (14).
Freshly isolated T lymphocytes represent a physiological
model system for the study of apoptosis in view of at least two
clear cut features: (i) resting lymphocytes are generally resist-
ant to various apoptotic stimuli including CD95/Fas ligation
(15); (ii) T cell activation, e.g. via phytohemagglutinin (PHA)
and/or interleukin-2 (IL-2) stimulation, leads to an increased
susceptibility to cell death in a process called activation-in-
duced cell death (16–18).
As a general rule, two different apoptotic pathways leading
to the activation of cell-specific programs have been proposed:
the “death receptor” and the “mitochondrial” pathways, involv-
ing caspase-8 and caspase-9, respectively (19). Both of them,
however, involve significant morphogenetic changes of mito-
chondria (20) as well as changes of mitochondrial membrane
potential (MMP), opening of the so-called mitochondrial mega-
pore, and release of apoptogenic factors (21). However, there is
still scarce information regarding the mechanisms underlying
susceptibility of resting or activated T cells to physiological or
pathological apoptotic stimuli.
In the present work we investigated the mechanisms under-
lying the proapoptotic activity exerted by Gal-1 in a physiolog-
ical cell system represented by resting as well as activated
human T cells. We found that this endogenous lectin can sen-
sitize resting T cells and bolster activated T cells to Fas-medi-
ated “physiological” cell death. The subcellular mechanism un-
derlying these effects involves glycosphingolipid-mediated
budding and fission of the mitochondria.
This is the first demonstration showing that Gal-1 sensitizes
* This work was supported by grants from the Ministry of Health and
National Research Council (to W. M.) and by grants from Wellcome
Trust, Antorchas Foundation, Sales Foundation, Ministry of Health
(Carrillo-On˜ativia Fellowship), and University of Buenos Aires Grant
UBACYT M091 (to G. A. R.). The costs of publication of this article were
defrayed in part by the payment of page charges. This article must
therefore be hereby marked “advertisement” in accordance with 18
U.S.C. Section 1734 solely to indicate this fact.
 These authors contributed equally to this work.
** Member of CONICET (Consejo Nacional de Investigaciones Cien-
tı´ficas y Tecnolo´gias).
‡‡ To whom correspondence should be addressed: Dept. of Drug Re-
search and Evaluation, Section of Cell Aging and Degeneration, Istituto
Superiore di Sanita´, Viale Regina Elena 299, Rome 00161, Italy. Tel.:
39-06-4990-2905; Fax: 39-06-4990-3691; E-mail: malorni@iss.it.
1 The abbreviations used are: Gal, galectin; Cyt c, cytochrome c; endo
G, endonuclease G; FB1, fumonisine B1; FITC, fluorescein isothiocya-
nate; HD, healthy donor; IL-2, interleukin-2; IVM, intensified video
microscopy; JC-1, 5–5,6–6-tetrachloro-1,1,3,3-tetraethylbenzimida-
zol-carbocyanine iodide; mAb, monoclonal antibody; MMP, mitochon-
drial membrane potential; Mon, monensin; PHA, phytohemagglutinin;
PI, propidium iodide; pNA, p-nitroanilide; TEM, transmission electron
microscopy; TRITC, tetramethylrhodamine isothiocyanate; UCP-2, un-
coupler protein 2.
THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 280, No. 8, Issue of February 25, pp. 6969–6985, 2005
© 2005 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in U.S.A.
This paper is available on line at http://www.jbc.org 6969
resting human T cells to undergo apoptosis. Elucidation of the
cellular and molecular mechanisms involved in Gal-1 effects is
essential for a complete understanding of the immunosuppres-
sive effects of this protein and its novel role in tumor-immune
privilege (14). This study also demonstrates that a dynamic
imbalance of mitochondrial fusion/fission processes can effec-
tively be involved in apoptosis of nonengineered freshly iso-
lated primary cells.
EXPERIMENTAL PROCEDURES
Isolation and Activation of Peripheral Blood Lymphocytes—Human
peripheral blood lymphocytes from healthy donors (HDs) were isolated
from freshly heparinized blood through a Ficoll-Hypaque density gra-
dient centrifugation and washed three times in phosphate-buffered
saline, pH 7.4 (Lympholyte-H, Cedarlane Laboratories, Hornby, On-
tario, Canada). Peripheral blood lymphocytes were subcultured in 25-
cm2 or 75-cm2 Falcon plastic flasks at a density of 1  106 cells/ml in
RPMI 1640 (Invitrogen) containing 15% fetal calf serum (Flow Labora-
tories, Irvine, Scotland, UK), 1% nonessential amino acids, 5 mM L-
glutamine, 100 IU/ml penicillin, and 100 mg/ml streptomycin at 37 °C
in a humidified 5% CO2 atmosphere. For peripheral blood lymphocyte
activation, CD3 T cells purified by magnetic beads (Dynal, Great
Neck, NY) were cultured for 72 h with 2 g/ml PHA (Roche Applied
Science) and 60 IU/ml IL-2 (Invitrogen).
Biochemical Characterization of Human Recombinant Gal-1—Hu-
man recombinant Gal-1 was obtained and purified as described by
Hirabayashi et al. (22). In brief, Escherichia coli strain BL21 (DE3)
(Novagen) was transformed with the pET21a/hGal1 plasmid (kindly
provided by Drs. Hirabayashi and K. I. Kasai), and human Gal-1 ex-
pression was assessed by immunoblotting. The recombinant protein
was purified by affinity chromatography on an asialofetuin-agarose
column and eluted with lactose after extensive washing of the column.
The hemagglutinating activity was measured as described previously
(10, 22), and the NH2-terminal amino acid sequence was determined
with an Applied Biosystems model 477A pulsed liquid sequencer (Ap-
plied Biosystems, Inc.). The lipopolysaccharide content of the purified
sample was less than 60 ng/mg protein, determined by a colorimetric
endotoxin determination reagent (Pyrodick, Seikagaku, Tokyo). The
eluted protein was reactive with an anti-Gal-1-specific polyclonal rabbit
antibody, and the minimum concentration of protein required for hem-
agglutinating activity was 1 g/ml (10, 22). The concentration-de-
pendent monomer/dimer status of Gal-1, assessed by nonreducing
PAGE and immunoblotting, is documented in Fig. 1A.
In Vitro Treatments—Previous to cell death, binding of Gal-1 to
human resting and activated T cells was performed using biotinylated
Gal-1 and FITC-streptavidin in the absence or presence of 30 mM
lactose as described previously (9). Isolated human T cells (resting or
PHA/IL-2-activated) were treated with different concentrations of Gal-1
(5, 20, 50, and 100 g/ml) for different time periods (6, 18, 36, and 72 h)
in association, or not, with 500 ng/ml anti-human Fas IgM mAb (-Fas,
clone CH11, Upstate Biotechnology, Lake Placid, NY). As a negative
experimental control an equal concentration of anti-CD3 IgM was also
employed. Gal-1 and CH11 treatments were also performed: (i) in the
presence of neutralizing anti-human Fas IgG1 mAb (clone ZB4, Upstate
Biotechnology, 250 ng/ml); (ii) in cells pretreated for 1 h with 5 M
ZVAD-CHO (a pan-caspase inhibitor, R&D Systems, Minneapolis); or
(iii) in cells incubated in the presence of 30 mM lactose. To evaluate the
involvement of ceramide-mediated signaling in Gal-1-induced apo-
ptosis, resting lymphocytes were pretreated for 1 h with a combination
of specific inhibitors of the ceramide pathway: 20 M fumonisine B1 (B1;
Sigma) and 10 M monensin (Mon; Sigma) (both solubilized in dimethyl
sulfoxide) before the addition of Gal-1. Although FB1 inhibits sphingo-
lipid and glycosphingolipid synthesis via (dihydro)ceramide synthesis
inhibition (23), Mon prevents ceramide generation through inhibition of
acidic sphingomyelinase (24). Dimethyl sulfoxide given alone was used
as an additional control.
Evaluation of Cell Surface Receptors—The surface expression of mol-
ecules associated with T cell activation (CD69, CD38, and HLA-DR) and
cell death (CD95/Fas) was assessed by flow cytometry on resting and
activated T lymphocytes treated with Gal-1. For this purpose, we used
fluorochrome-conjugated FITC or mAbs raised against human CD95,
CD38, HLA-DR and CD69 (BD Biosciences). Appropriate fluorochrome-
conjugated mAbs of the same isotype were used as negative controls.
Cell Death Assays—Quantitative evaluation of apoptosis was per-
formed by using the following flow and static cytometry methods: (i)
double staining using FITC-conjugated annexin V/propidium iodide (PI)
apoptosis detection kit (Eppendorf, Milan, Italy); (ii) staining with
chromatin dye Hoechst (Molecular Probes, Eugene, OR), as described
previously (25); and (iii) evaluation of DNA fragmentation in ethanol-
fixed cells using PI (Sigma) (data not shown). To rule out the possibility
that Gal-1-induced cell agglutination may damage the cells, we incu-
bated the cells with 30 mM lactose to dissociate cell clusters after Gal-1
binding and before cell death assays.
Analysis of the MMP—The MMP of control and treated cells was
studied by using the JC-1 probe. Briefly, cells were stained with 10 M
JC-1 (Molecular Probes) as described previously (26). Tetramethylrho-
damine ester (1 M, TMRM, Molecular Probes, red fluorescence) was
also used to confirm the data obtained using JC-1.
Cell Cycle Analyses—For DNA analysis ethanol-fixed lymphocytes
FIG. 1. Biochemical and functional characterization of human
recombinant Gal-1. A, monomer-dimer status of purified recombinant
Gal-1 at concentrations ranging from 5 to 100 g/ml used for functional
assays. Samples were run on a 15% nondenaturing polyacrylamide gel,
transferred onto nitrocellulose membranes, and incubated with a spe-
cific rabbit anti-Gal-1 polyclonal Ab. B, for binding assays 5  105
PHA/IL-2-activated or resting T cells were incubated for 1 h with 20
g/ml biotinylated Gal-1 in the absence (gray histograms) or presence
(black empty histograms) of 30 mM lactose. Cells were then incubated
with FITC-streptavidin for 45 min and analyzed by flow cytometry.
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FIG. 2. Gal-1 sensitizes resting and activated T lymphocytes to Fas-mediated cell death. A, percentage of apoptosis as revealed by flow
cytometry analysis of resting and PHA/IL-2-activated freshly isolated human T lymphocytes after annexin V-FITC staining. The first row includes
controls; the second row shows apoptosis induced by -Fas triggering (CH11); the third row indicates resting and activated cells cultured with 20
g/ml Gal-1 in the absence of other stimuli; the fourth row indicates association of CH11 and Gal-1. Results obtained from a representative HD
are shown. Numbers indicate the percentage of annexin V-positive cells. Similar results were obtained by the analysis of hypodiploid peaks after
PI staining (not shown). B, mean values  S.D. obtained by pooling together data from 12 different HDs. Asterisks (*) represent p  0.01. Note
that the presence of 30 mM lactose significantly prevented Gal-1 effects.
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were incubated with g/ml PI (Sigma) and 10 M RNase (Sigma) for 45
min. After this time period, samples were acquired directly on a FAC-
Scan flow cytometer by CellQuest software (BD Biosciences). At least
20,000 events for each sample were statistically analyzed by ModFIT
software for Macintosh to determine the percentage of cells in G0/G1, S,
and G2/M phases, respectively.
Analysis of the Redox Balance—Resting and PHA/IL-2-activated hu-
man T lymphocytes (5  105 cells), cultured in the presence or absence
of Gal-1, were incubated in 495 l of Hanks’ balanced salt solution (pH
7.4) containing 10 M dihydrorhodamine 123 (Molecular Probes) or 1 M
dihydroethidium (Molecular Probes) in polypropylene test tubes for 15
min at 37 °C. Intracellular content of reduced thiols was explored by
using 10 M 5-chloromethyl-2,7-dichloro-dihydrofluoresceindiacetate
(Molecular Probes). Cells exposed to the GSH depleting drug L-buthi-
onine-[S,R]-sulfoximine (7.5 mM; Sigma) for 16 h were considered as
negative controls (data not shown). The median values of fluorescence
FIG. 3. Gal-1 sensitizes resting T cells to Fas-mediated apoptosis in a dose-dependent manner. A, biparametric flow cytometry analysis
of resting lymphocytes after double staining with annexin V-FITC/PI. A, left column, T lymphocytes treated with increasing doses of recombinant
human Gal-1; right column, T cells treated with Gal-1  CH11 combination. In the upper and lower right quadrants of each plot, annexin V/PI
double positive cells and annexin V single positive cells are represented, respectively. Results obtained from a representative HD are reported. B,
mean values S.D. of the percentages of annexin V-positive cells obtained by evaluating cells from 12 different HDs. Statistical analyses indicated
that (i) 50 and 100 g/ml Gal-1 exposure induced per se annexin V staining of human resting T lymphocytes and that (ii) Gal-1 significantly
bolstered anti-Fas-induced cell death (p  0.01).
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intensity histograms were used to provide semiquantitative assessment
of reduced thiols content and reactive oxygen intermediates production.
Analysis of Caspase Activation—For detection of the active form of
caspases-8, -9, and -3, colorimetric protease assay kits (Chemicon In-
ternational, Inc.) were used. Proteins obtained from cytosolic extracts
(50–200 g) were incubated with 200 M IETD-pNA (for caspase-8),
LEHD-pNA (for caspase-9) or DEVD-pNA (for caspase-3). The assay
was based on the spectrophotometric detection of the chromophore
p-nitroanilide (pNA) after cleavage from the labeled substrates. p-NA
light emission was quantified using a microtiter plate reader at 405 nm.
Comparison of the absorbance of p-NA from apoptotic samples with
nonstimulated controls allowed determination of the-fold increase in
caspase activity (27).
Immunocytochemistry—Immunofluorescence analyses were per-
formed by double staining as follows. Briefly, control and treated sam-
ples were incubated, with 1 M Mito Tracker Green FM (Molecular
Probes) at 37 °C for 30 min. Then, cells were washed, fixed with 4%
paraformaldehyde (w/v in phosphate-buffered saline) for 1 h at room
temperature, and then permeabilized by 0.5% (v/v) Triton X-100. For
localization and quantification of h-Fis, DRP-1 and uncoupler (UCP)
proteins, samples were incubated for 1 h at room temperature with
mAbs specific to h-Fis (Alexis Biochemicals, San Diego), DRP-1 (BD
Biosciences), or UCP-2 (Calbiochem). Negative controls were incubated
with normal mouse serum. After several washings, samples and isotype
controls were incubated for 45 min at room temperature with TRITC-
conjugated anti-mouse IgG (Sigma). All samples were mounted with
glycerol phosphate-buffered saline (2:1) and analyzed by Intensified
Video Microscopy (IVM) as stated elsewhere (28) or analyzed by
flow cytometry.
Analysis of Fas Ligand Secretion—Fas ligand levels were determined
in supernatants of lymphocytes cultured in the presence or absence of
Gal-1, using a sensitive enzyme-linked immunosorbent assay kit
(R&D). Briefly, resting and PHA/IL-2-activated lymphocytes were ex-
posed to Gal-1 for different time periods. Supernatant aliquots were
removed 6, 18, 36, and 72 h after exposure to Gal-1 and assayed for Fas
ligand secretion according to the manufacturer’s instructions.
Analysis of Cytochrome c Release—Cytochrome c (Cyt c) was evalu-
ated by a sensitive and specific immunoassay, using a commercial
enzyme-linked immunosorbent assay kit according to the manufactur-
er’s instructions. The light emitted was quantified by using a microtiter
plate reader at 405 nm. Cyt c concentration was expressed as g/ml.
Transmission Electron Microscopy (TEM)—For TEM examination,
cells were fixed in 2.5% cacodylate-buffered (0.2 M, pH 7.2) glutaralde-
hyde for 20 min at room temperature and postfixed in 1% OsO4 in
cacodylate buffer for 1 h at room temperature. Fixed specimens were
dehydrated through a graded series of ethanol solutions and embedded
in Agar 100 (Agar Aids, Cambridge, UK). Serial ultrathin sections were
collected on 200-mesh grids and then counterstained with uranyl ace-
tate and lead citrate. Sections were observed with a Philips 208 electron
microscope at 80 kV.
Morphometric Analyses—Analyses of mitochondrial intracellular lo-
calization were carried out by TEM observation of at least 200 cells at the
same magnification (3,000). Values were expressed as the percentage of
cells displaying clusters of mitochondria at one pole of the cells with
respect to lymphocytes with randomly distributed mitochondria.
Immunoelectron Microscopy—Thin sections, collected on gold grids,
were treated with phosphate-buffered saline containing 1% (w/v) gela-
tin, 1% bovine serum albumin, 5% fetal calf serum, and 0.05% Tween 20
and then incubated with mAbs raised against anti-Cyt c, endonuclease
G (endo G), DRP-1, and h-Fis diluted 1:10 in the same buffer without
gelatin overnight at 4 °C. After washing for 1 h at room temperature,
sections were labeled with a protein A-10 nm gold conjugate (1:10) for
1 h at room temperature and washed again. Negative controls were
incubated with the gold conjugate alone.
Data Analysis and Statistics—All samples were analyzed with a
FACScan cytometer (BD Biosciences) equipped with a 488 argon laser.
At least 20,000 events were acquired. Data were recorded and analyzed
statistically by a Macintosh computer using CellQuest Software. The
expression level of the analyzed proteins was expressed as a median
value of the fluorescence emission curve, and the statistical significance
was calculated by using the parametric Kolmogorov-Smirnov test. Sta-
tistical analyses of apoptosis data were performed by using Student’s t
test or one-way analysis of variance using the Statview program for
Macintosh. All data reported were verified in 12 different HDs and are
expressed as the mean  S.D. Only p values of less than 0.01 were
considered as statistically significant.
RESULTS
Gal-1 Sensitizes Resting T Cells to Anti-Fas (-Fas)-mediated
Apoptosis in a Dose-dependent Manner—The first set of exper-
iments was carried out to evaluate the ability of recombinant
Gal-1 to modulate the susceptibility of human freshly isolated T
cells, both resting and PHA/IL-2-activated, to Fas (CD95)-medi-
ated apoptosis. Recombinant human Gal-1 was obtained, puri-
fied, and characterized, as described under “Experimental Pro-
cedures” (see also Fig. 1). The lipopolysaccharide content of the
purified protein was less than 60 ng/mg protein as has been
described previously (22). Before the cell death assays we ana-
lyzed binding of biotinylated Gal-1 to human resting and acti-
vated T cells. Biotinylated Gal-1 (20 g/ml) bound with higher
affinity to PHA/IL-2-activated, compared with resting human T
cells (Fig. 1B; gray histograms). Gal-1 binding to activated and
resting T cells was inhibited completely in the presence of 30 mM
lactose, demonstrating that binding was specific and saccharide-
dependent (Fig. 1B, black empty histograms).
We observed that Gal-1, at a concentration of 20 g/ml, was
capable of inducing a time-dependent phosphatidylserine expo-
sure and annexin V binding in a significant percentage of
activated T cells. In particular, the percentages of annexin
V-positive cells were 7.9%  2.3% after 6 h, 12.3%  3.0% after
18 h, and 22.1%  4.9% after 36 h. Results obtained after 72 h
of Gal-1 exposure are reported in Fig. 2A (a representative HD,
third row, right panel) and Fig. 2B (mean values from 12
different HDs). By contrast, the same Gal-1 concentration was
ineffective toward resting T lymphocytes (Fig. 2A, third row,
left panel). Importantly, the presence of 30 mM lactose com-
pletely inhibited Gal-1-induced phosphatidylserine exposure in
both resting and activated lymphocytes (Fig. 2B). Control ex-
periments carried out using the anti-Fas mAb (clone CH11)
clearly pointed out the powerful proapoptotic activity elicited
by Fas ligation on activated cells, i.e. the so-called activation-
induced cell death (17) (Fig. 2A, second row, right panel). In-
terestingly, exposure to 20 g of Gal-1 significantly sensitized
resting lymphocytes to anti-Fas apoptotic triggering inducing
higher apoptotic rates (36.7%) compared with control samples
(Fig. 2A, bottom row, left panel, % Gal-1 CH11 versus CH11
alone  86.6%). In the same vein, in activated T cells, Gal-1
treatment further increased the effects induced by CD95 en-
gagement, significantly bolstering apoptosis (60.4%, Fig. 2A,
bottom row, right panel). Results obtained by pooling together
data from blood samples of 12 different HDs are reported in
Fig. 2B.
A dose-dependent response could be observed when human T
cells were exposed to increasing concentrations of Gal-1 (Fig.
3A). In particular, doses of Gal-1 ranging from 20 to 100 g/ml
induced a significant (p  0.01) sensitization to anti-Fas apo-
ptotic triggering (Fig. 3A, a representative HD, compare right
panel with left panel, upper and lower right quadrants). Strik-
ingly, considering the general resistance of resting T cells to
apoptosis (15, 16), we have noticed that a relatively high con-
TABLE I
Effects of Gal-1 on the expression of activation markers
Flow cytometry analysis of surface expression of CD69, HLA-DR, and
CD38 in resting and IL-2/PHA-activated T cells after 20 g/ml Gal-1
treatment for 72 h is shown. Numbers represent the mean S.D. of the
median values of the fluorescence intensity histograms from four dif-
ferent experiments.
Resting PHA/IL-2-activated
Control Gal-1 Control Gal-1
CD69 1.9  0.5 1.7  0.4 15.9  3.1 14.9  1.9
HLA-DR 47.8  7.9 50.1  6.3 385.4  23.1 383.9  22.5
CD38 15.2  2.2 15.9  1.7 83.5  10.0 82.9  9.1
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FIG. 4. Association of Fas and Gal-1 in the execution of T cell death. Flow cytometry analysis of CD95 surface expression in (A) resting
T cells and (C) PHA/IL-2-activated T lymphocytes is shown. Note that the presence of 20 g/ml Gal-1 significantly increased CD95 expression in
resting cells but not in activated cells. B, flow cytometry evaluation of CD95/Fas surface expression in resting lymphocytes treated with increasing
concentrations of Gal-1. Numbers represent median values of fluorescence intensity histograms (M) obtained from a representative HD. D, analysis
of Fas ligand secretion by a capture enzyme-linked immunosorbent assay. Data from six different HDs are reported. No significant changes were
detectable in resting or activated T cells after Gal-1 treatment compared with controls. E–G, biparametric flow cytometry analysis after double
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centration of Gal-1 (100 g) (6, 8) was per se a powerful apo-
ptotic inducer in human resting T cells (Fig. 3A, last row,
representative HD). Mean values obtained by pooling together
median values from 12 different HDs are reported in Fig. 3B.
Subcellular Effects Triggered by Gal-1 on Resting and Acti-
vated T Cells—In light of the above findings, we next evaluated
the expression of relevant cell surface markers and cellular
mediators associated with cell activation and cell fate in resting
and activated lymphocytes after exposure to Gal-1. Our atten-
tion was essentially focused on: (i) cell activation markers, (ii)
CD95/Fas expression, and (iii) Fas ligand expression and se-
cretion. Moreover, in consideration of the role of reactive oxy-
gen intermediates in disturbing cell homeostasis and modulat-
ing cell apoptosis (29), we also explored the redox state of
Gal-1-treated and untreated cells. Regarding activation mark-
ers, no changes could be detected after Gal-1 treatment in
either resting or activated T cells. In particular, CD69, major
histocompatibility complex class II, and CD38 remained un-
changed in Gal-1-exposed cells compared with controls (Table
I). Thus, Gal-1 was not able per se to modulate expression of T
cell activation markers. In contrast, we observed a significant
(p  0.01) up-regulation of CD95/Fas expression on the surface
of resting T lymphocytes exposed to Gal-1 (Fig. 4A; a represent-
ative HD is shown). Mean values obtained from median values
of fluorescence intensity histograms in resting cells from 12 HD
are as follows: control  9.4  1.5%: Gal-1  16.2  2.4% (p 
0.01). Interestingly, we found a dose-dependent up-regulation
of this molecule on the surface of resting cells treated with
Gal-1 (Fig. 4B). By contrast, under our experimental condi-
tions, PHA/IL-2-activated cells did not display significant
changes in CD95/Fas surface expression after Gal-1 treatment
(Fig. 4C). In fact, mean values obtained by pooling together
median values of fluorescence intensity histograms in activated
T lymphocytes from 12 HDs were the following: PHA/IL-2 
30.3  4.5; PHA/IL-2  Gal-1  32.4  5.1% (p 	 0.05). The
influence of Gal-1 on Fas ligand secretion was also evaluated
under the same experimental conditions in the culture medium
of treated and untreated cells. However, no significant changes
were detected between control and Gal-1-treated lymphocytes,
either in culture medium from resting or PHA/IL-2-activated T
cells (Fig. 4D). Accordingly, when intracellular and surface
expression of Fas ligand was evaluated, no significant changes
were found after Gal-1 treatment (data not shown).
Next, a specific set of experiments was carried out to analyze
three critical parameters known to influence the redox balance
of the cell: (i) production of superoxide, (ii) hydrogen peroxide,
and (iii) the intracellular content of reduced thiols. As shown in
Table II, no significant changes were detected in the redox
state of resting cells after treatment with both Gal-1 and anti-
Fas mAb. In contrast, in PHA/IL-2-activated T cells, we found
a significant increase in hydrogen peroxide production after
Gal-1 treatment and a significant increase in thiol content in
Gal-1 as well as in anti-Fas-treated cells (Table II shows me-
dian values of the fluorescence intensity histograms obtained
by flow cytometry). Importantly, no significant changes were
detected between Gal-1-treated and control cells in terms of cell
proliferation and cell cycle (Table III).
On the basis of our findings, we next performed a set of
experiments aimed at elucidating the association between
Gal-1 and Fas-mediated apoptosis. For this purpose we used
the anti-Fas-blocking mAb (clone ZB4) and analyzed the per-
centage of annexin V/PI-positive cells (Fig. 4E). As a control, we
used the anti-Fas-blocking mAb ZB4 on PHA/IL-2-activated T
lymphocytes treated with anti-Fas-triggering mAb (clone
CH11) (Fig. 4F). As expected, ZB4 was able to counteract anti-
Fas (CH11)-induced apoptosis significantly in activated T cells
(Fig. 4F; a representative HD; compare the middle panel with
the bottom panel). More importantly, we found that in the
presence of the ZB4 blocking mAb, a significant reduction of
Gal-1-induced cell death clearly occurred in resting cells (Fig.
4E, compare the middle panel with the bottom panel). The
results obtained by pooling together data from 12 different HDs
clearly indicated that CD95/Fas-blocking mAb ZB4 was able to
prevent Gal-1-induced cell death significantly in resting cells
(  50%; Fig. 4G).
Influence of Gal-1 on MMP of Resting Human T Lympho-
cytes—To deep inside the molecular mechanisms involved in
Gal-1 sensitization to anti-Fas-induced cell death we analyzed
MMP in resting cells sensitized to Fas triggering by exposure to
Gal-1 (Fig. 5, A–F). We found an increased MMP in a signifi-
TABLE II
Influence of Gal-1 on the redox state of human T cells
Semiquantitative cytofluorometric analysis of hydrogen peroxide production, superoxide anion production, and intracellular reduced thiols
content in resting and activated T lymphocytes after different treatments (20 g/ml, 72 h) are shown. Numbers represent the mean  S.D. of the
median values of the fluorescence intensity histograms from four different experiments.
Resting Activated
Control Gal-1 -Fas Gal-1  -Fas Control Gal-1 -Fas Gal-1  -Fas
H2O2 82.8  9 79.7  8 79.1  7 106.9  11 115.5  10 160.9  12 100.3  9 174.8  17
O2 63.8  7 66.7  9 64.4  6 65.4  6 73.6  8 74.3  8 77.7  6 76.9  9
Thiols 210.9  23 229.7  19 234.8  25 279.8  29 399.5  31 491.4  39 454.2  34 499.4  41
TABLE III
Effects of Gal-1 on cell cycle and proliferation of human T cells
Cytofluorometric analysis of the cell cycle of resting and PHA/IL-2-
activated T cells after 20 g/ml Gal-1 treatment for 72 h is shown.
Numbers represent the mean percentage S.D. of cells in G0/G1, S, and
G2/M phases from three independent experiments, respectively. Statis-
tical analysis was performed by ModFIT software for Macintosh. Effects
of Gal-1 treatment on cell proliferation are expressed as cell no./ml
(bottom row).
Resting PHA/IL-2-activated
Control Gal-1 Control Gal-1
G0/G1 (% of cells) 92.9  2.1 93.0  1.9 78.7  1.7 79.2  2.0
S (% of cells) 2.7  0.6 2.5  0.5 11.3  2.1 10.0  2.2
G2/M (% of cells) 4.4  1.1 4.5  1.0 10.0  1.8 10.8  1.9
Cell no. (  105/ml) 6.7  0.2 6.5  0.7 7.6  1.0 7.4  1.3
staining with annexin V-FITC/PI of (E) resting T lymphocytes treated with 100 g/ml Gal-1 in the presence or absence of -Fas blocking mAb (ZB4
clone). In F, PHA/IL-2-activated lymphocytes were treated with -Fas-mAb (CH11) in the presence or absence of ZB4, a control, to evaluate the
antagonistic activity of ZB4 mAb. In the upper and lower right quadrants, the percentages of annexin V/PI double positive cells and annexin V
single positive cells are included, respectively. Results obtained from a representative HD are reported. G, mean values  S.D. of the percentages
of annexin V-positive cells obtained by evaluating cells from 12 different HDs. Statistical analyses indicate a significant (p  0.01) inhibition of
apoptosis by the ZB4 antagonist mAb in Gal-1-treated resting T lymphocytes (red columns). Note that ZB4 mAb treatment also prevented
-Fas-mAb (CH11)-induced apoptosis in PHA/IL-2-activated T lymphocytes (positive control, blue columns).
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cant percentage of Gal-1-treated resting T lymphocytes (Fig.
5B; the boxed area shows the percentage of cells with hyperpo-
larized mitochondria). By contrast, and according to apoptosis
data (see Fig. 2): (i) anti-Fas mAb given alone (clone CH11) did
not induce any significant change in MMP (Fig. 5C, boxed area)
whereas (ii) Gal-1/CH11 association also induced in resting
lymphocytes the loss of MMP in a significant percentage of
cells, a typical afterward modification associated with apo-
ptosis execution (Fig. 5D, lower right quadrant). Noteworthy,
the association of Gal-1 with anti-Fas (CH11) left substantially
unchanged the percentage of cells with hyperpolarized mito-
chondria with respect to cells treated with Gal-1 alone (Fig. 5D
FIG. 5. Modulation of MMP by Gal-1 in human resting T lymphocytes. Biparametric flow cytometry analysis of MMP of resting T
lymphocytes after staining with JC-1 (A–D). A, control; B, 20 g/ml Gal-1; C, -Fas mAb (CH11); and D, association of -Fas mAb (CH11) and Gal-1.
E, PHA/IL-2-activated T lymphocytes (positive control for mitochondrial membrane hyperpolarization). Numbers reported in the boxed area
represent the percentages of cells with hyperpolarized mitochondria. In the lower right quadrants the percentages of cells with depolarized
mitochondria are shown. In A–E, results obtained from a representative HD are shown. F, mean values  S.D. of the percentages of cells with
hyperpolarized mitochondria obtained by evaluating six different HDs. Statistical analyses indicated a significant (p  0.01) increase of cells with
hyperpolarized mitochondria in resting T lymphocytes treated with Gal-1 and the -Fas mAb (CH11) and in PHA/IL-2-activated T lymphocytes
(positive control) with respect to untreated resting cells. Note that the presence of 30 mM lactose significantly prevented mitochondrial membrane
hyperpolarization.
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versus Fig. 5B). As a positive control for this set of experiments,
we used PHA/IL-2-activated lymphocytes, which show hyper-
polarized mitochondria as a “default” feature, as reported pre-
viously (30–32) (Fig. 5E, boxed area). In summary, data ob-
tained by analyzing T cells from 12 different HDs (reported as
mean values in Fig. 5F) clearly indicate that: (i) when resting
cells were exposed to Gal-1 or Gal-1  CH11, an increased
MMP was detectable (Gal-1  42.1  8.1; Gal-1  CH11 
43.3 9.4) and, importantly (ii) in these cells CH11 given alone
did not influence MMP. Furthermore, these effects were almost
completely prevented using -galactoside-related sugars such
as lactose (30 mM). In fact, lactose also inhibited the effects
induced by Gal-1 at the mitochondrial level (Fig. 5F). A sum-
mary of the findings observed upon Gal-1 treatment of human
lymphocytes is shown in Table IV.
Considering these observations, we next explored time-de-
pendent changes in MMP on human resting T cells after Gal-1
treatment. As shown in Fig. 6, very early after Gal-1 treatment,
an increased MMP, i.e. a hyperpolarization of mitochondrial
membrane, was detected in a high percentage of cells (Fig. 6, B
and C, 6 and 18 h, respectively, see boxed area) followed by a
typical depolarization, as a later event (Fig. 6, D and E, 36 and
72 h, respectively, see the lower right quadrant). In these
experiments, the release of Cyt c was also assessed (Fig. 6F).
Importantly, the percentage of cells in which we observed the
loss of MMP corresponded to the percentage of lymphocytes
that showed surface exposure of phosphatidylserine as a typi-
cal feature of apoptosis (compare Fig. 6, A–E, with Fig. 7A).
Characterization of the Gal-1-mediated Apoptotic Pathway—
Apoptosis is generally associated, as a late event, with the loss
of MMP, the release of apoptogenic factors, e.g. apoptosis-in-
ducing factor, endo G, and Cyt c and the consequent activation
of caspase-9, which triggers the execution of cell death (17).
To gain insight the intracellular signaling pathways trig-
gered by Gal-1, we performed a parallel analysis of caspase
activity in the presence of the pan-caspase inhibitor ZVAD.
Results clearly indicated that Gal-1 treatment induced a time-
dependent activation of caspase-8 (Fas-associated caspase, Fig.
7B), caspase-9 (mitochondria-associated caspase, Fig. 7C), and
the executioner caspase-3 (Fig. 7D). In particular, after 6 h of
Gal-1 treatment, only caspase-8 (Fig. 7B), but not caspases-9
(Fig. 7C) or -3 (Fig. 7D) was activated. Accordingly, at this time,
no release of Cyt c was observed (data not shown). However,
prolonging the exposure to Gal-1 resulted in a time-dependent
activation of caspases-9 and -3 (Fig. 7, C and D).
Considering the role of ceramide as a second messenger in
FIG. 6. Time course analysis of the modulation of MMP and Cyt c release by Gal-1. MMP were assessed by flow cytometry in resting T
lymphocytes incubated in the absence (A) or presence of Gal-1 for 6 (B), 18 (C), 36 (D), and 72 h (E) and then stained with JC-1 (A–E). In the boxed
areas the percentage of cells with high MMP are reported; numbers in the lower right quadrants indicate the percentage of cells with depolarized
mitochondria. F, evaluation of Cyt c released from resting T lymphocytes. Note the dose-dependent effect of Gal-1.
TABLE IV
Effects of Gal-1 on human T cells
Changes induced by Gal-1 (20 g/ml, 72 h) in resting and IL-2/PHA-
activated T lymphocytes are shown.
Resting IL-2/PHA-activated
Fas-mediated apoptosis Increased Increased
Gal-1-induced apoptosis No changes Increased
CD95 expression Increased No changes
Fas ligand secretion No changes No changes
Reactive oxygen species production No changes Increased
Mitochondria hyperpolarization Yes Yes
Cell proliferation No changes No changes
Cell cycle No changes No changes
Expression of activation markers No changes No changes
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CD95-mediated apoptosis (33) and the potential role of this
intracellular mediator in T cell death induced by certain galec-
tins (34), FB1 and Mon were used as specific inhibitors of the
ceramide signaling pathway. Results obtained clearly showed
that the administration of FB1 and Mon was able to signifi-
cantly prevent apoptosis induced by exposure to Gal-1 (Fig. 8,
D versus C; p  0.01). In particular, annexin V binding was
decreased significantly (60%) in resting T cells preexposed to
ceramide inhibitors 1 h before the addition of Gal-1 (Fig. 8D).
Accordingly, a significant inhibition of apoptosis-associated
MMP loss was also observed (data not shown). Spectrophoto-
metric analysis of the activation state of caspases-8, -9, and -3
also confirmed these data (Fig. 8E), the absorbance values
obtained after Gal-1 exposure being significantly higher than
those found in T lymphocytes pretreated with a mixture of FB1
and Mon before the addition of Gal-1 (p  0.01).
Effects of Gal-1 on Mitochondrial Coalescence, Budding, and
Fission—On the basis of recent data describing a role for mi-
tochondrial compartment “remodeling” in apoptotic cell death
(20, 35), a specific set of experiments was performed aimed at
FIG. 7. Characterization of the Gal-
1-mediated apoptotic pathway: in-
volvement of caspases. A, cell death
was examined by flow cytometry after an-
nexin V staining of Gal-1-treated or un-
treated cells in the absence or presence of
the pan-caspase inhibitor ZVAD. Activa-
tion state of caspase-8 (B), caspase-9 (C),
and caspase-3 (D) in Gal-1-treated or un-
treated lymphocytes in the presence or
absence of the pan-caspase inhibitor
ZVAD is shown. As expected, ZVAD sig-
nificantly (p 0.01) prevented either apo-
ptosis (A) or caspase-8 (B), caspase-9 (C),
and caspase-3 (D) activation induced by
Gal-1.
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analyzing ultrastructural features of mitochondria in Gal-1-
treated resting cells and the behavior of key molecules involved
in mitochondrial changes occurring in the early stages of apo-
ptosis, i.e. h-Fis and DRP-1 (20, 35, 36). Our observations are
summarized in Figs. 9–12. The sequence of events occurring in
mitochondria after Gal-1 exposure were the following: (i) mito-
chondria, scattered throughout the cell cytoplasm in control
untreated resting T lymphocytes (Fig. 9A), underwent redistri-
bution at one pole of the cells after Gal-1 treatment (Fig. 9B).
Next, (ii) a massive coalescence and clustering of the mitochon-
dria was observed (Fig. 9C). Morphometric analyses carried out
by TEM clearly demonstrated a significant increase of cells
with clustered and marginalized mitochondria after Gal-1
treatment (Fig. 9D). Furthermore, in light of the results shown
in Fig. 5, we evaluated the correlation between the percentages
of cells displaying mitochondria with increased  and cells
with “marginalized” mitochondria. This analysis clearly indi-
cated a statistically significant correlation (r  0.8979; p 
0.001) between these two events. Moreover, we observed elec-
trondense mitochondrial membranes budding from the mito-
chondrial “body” (Fig. 9E), which finally formed small pedun-
culated and whorled membrane structures (Fig. 9, F and G). In
FIG. 8. Role of the ceramide pathway in Gal-1-induced cell death. Analysis of cell death after double staining with annexin V-FITC/PI.
A, control cells; B, cells treated with a combination of FB1 and Mon (inhibitors of the ceramide pathway); C, cells exposed to Gal-1 alone or D, in
the presence of a FB1/Mon combination. Numbers in the upper and lower right quadrants indicate the percentages of annexin V/PI double positive
and annexin V single positive cells, respectively. E, spectrophotometric analysis of caspases-8, -9, and -3 activation under the conditions described
above. Asterisks (*) represent p  0.01.
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FIG. 9. Ultrastructural analysis of resting T lymphocytes treated with Gal-1. A, randomly distributed mitochondria were detectable in
control cell cytoplasm. B, after exposure to Gal-1 for 18 h, mitochondria appeared clustered at one pole of the cell, undergoing coalescence (C,
arrow). D, quantitative morphometric analyses revealed that the percentage of cells displaying mitochondrial clustering at one pole of the cell was
increased significantly after 6 and 18 h of Gal-1 treatment. Asterisks (*) indicate a significant (p  0.01) difference versus control untreated
samples. Alterations of mitochondria occurring at early stages of apoptosis in Gal-1-treated resting T lymphocytes are shown in E–H. After an 18-h
Gal-1 treatment, mitochondrial membrane budding structures were visible as small electron dense “blebs” (E, arrows). After a 36-h treatment,
pedunculated membranous structures (F and G, arrows), sometimes whorled and detached from the organelle surface (F, arrowheads), were
detected. Budding structures could also result in the formation of a sort of “newborn organelle” (H, arrow).
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some cases, these structures appeared detached from the mi-
tochondrial body (Fig. 9F). These changes resulted in the for-
mation of a small organelle with typical features of mitochon-
dria (Fig. 9H). Notably, these changes were observed neither in
control resting T cells nor after exposure to anti-Fas mAb.
Considering these observations, we next investigated the
participation in this process of key molecules (h-Fis and DRP-
1), which have been associated with morphogenetic changes
occurring in mitochondria of dying cells. Both quantitative (by
flow cytometry) and qualitative (by static cytometry) analyses
were performed. Early after Gal-1 exposure (from 6 to 36 h), we
found a time-dependent increase in h-Fis expression (Fig. 10A).
This overexpression was, however, transient, and after 72 h
h-Fis expression dropped down to lower “basal” levels. Parallel
analyses carried out by IVM (Fig. 10B) showed a redistribution
of this molecule in accordance with mitochondrial marginaliza-
tion and coalescence as revealed by TEM analyses (Fig. 9B).
More importantly, h-Fis appeared to be colocalized with polar-
ized mitochondria (Fig. 10B). This observation was suggested
by overlapping of green fluorescence (mitochondrial labeling)
and red fluorescence (h-Fis), resulting in yellow staining in the
merged pictures (see right column in Fig. 10B). Parallel anal-
ysis was also carried out to evaluate DRP-1 quantitative ex-
pression and intracellular localization (Fig. 11). Differently
from h-Fis, no significant quantitative changes in DRP-1 ex-
pression were detected in Gal-1-treated cells with respect to
control cells (Fig. 11A). By contrast, a well evident redistribu-
tion of DRP-1 molecule was detected in Gal-1-exposed resting T
FIG. 10. Evaluation of h-Fis expres-
sion and subcellular distribution in
resting T lymphocytes. A, quantitative
flow cytometry analysis of h-Fis protein
expression in T lymphocytes treated with
Gal-1 for 6, 18, 36, and 72 h. Statistical
analyses (Kolmogorov-Smirnov test) indi-
cated a significantly (p  0.01) increased
expression of h-Fis. However, after a 72-h
Gal-1 treatment, values detected were
similar to those found in control samples
(p 	 0.05). Numbers reported in A indi-
cate the median values of fluorescence in-
tensity histograms obtained in T lympho-
cytes from a representative HD. B,
intracytoplasmic localization of h-Fis ob-
tained by IVM technique after double
staining of Gal-1-treated T lymphocytes
with a Mito Tracker Green probe (to de-
tect mitochondria) and TRICT-conjugated
mAb to h-Fis (red fluorescence). Fluores-
cence micrographs show that h-Fis is lo-
calized at one pole of T cells 18 or 36 h
after Gal-1 treatment and is colocalized
with mitochondria as demonstrated by
merged pictures in the right column. Re-
sults obtained from a representative of
eight HDs are reported.
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lymphocytes by IVM analyses (Fig. 11B). In particular, starting
from 6 h of Gal-1 treatment (second row), DRP-1 (red fluores-
cence) appeared to be organized as small spots, which colocal-
ized to mitochondria (green fluorescence) resulting in the yel-
low staining visible in the merged pictures.
To deep inside the mechanisms involved in the mitochondrial
FIG. 11. Evaluation of DRP-1 expression and localization in Gal-1-treated resting T lymphocytes. Quantitative (A) and qualitative (B)
analyses were carried out by flow cytometry and static IVM cytometry. A, no significant increase of DRP-1 expression (p 	 0.05 by Kolmogorov-
Smirnov test) was detected after Gal-1 treatment. Conversely, fluorescence micrographs (B) clearly indicated that mitochondria (revealed by Mito
Tracker Green staining) and DRP-1 protein (detected by TRICT-conjugated mAb, in red) colocalize in untreated T lymphocytes (first row) as well
as after a 6-h (second row) or 18-h (third row) Gal-1 exposure. After 36 h (fourth row), only a partial colocalization was detectable. Furthermore,
both DRP-1 and mitochondria appeared distributed randomly in untreated T lymphocytes (first row) and marginalized after Gal-1 exposure (note
the merged pictures on the right). The scattered positivity detectable after 36 h (fourth row) is suggestive of mitochondrial budding (compare with
Fig. 9). Results obtained from a representative of eight HDs are shown.
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changes induced by Gal-1, we also analyzed the expression and
localization of UCP-2, an important endogenous protein in-
volved in mitochondrial homeostasis (37). However, in our ex-
perimental system, Gal-1 treatment did not induce any signif-
icant modification in the expression of UCP-2 in resting
lymphocytes (median values of fluorescence intensity histo-
grams obtained by flow cytometry: 121.9  12.3 in control cells
and 119.7  13.5 in Gal-1-treated cells).
Finally, TEM analyses of two key mitochondria-associated
molecules of importance in the apoptotic cascade, Cyt c and
endo G, were carried out by means of immunogold labeling
postembedding technique (Fig. 12, A and B). The aim of these
analyses was to evaluate the possible selective presence of
these molecules in the budding regions of mitochondria. We
found the presence of endo G (Fig. 12A) and Cyt c (Fig. 12B) in
the budding regions as well as in the mitochondrial body and
the cell cytoplasm of Gal-1-treated cells. Conversely, immuno-
gold analyses regarding the mitochondrial fission-associated
molecules h-Fis (Fig. 12C) and DRP-1 (Fig. 12D), clearly
showed a different behavior of these proteins. In fact, h-Fis
appeared associated with mitochondria outer and inner mem-
branes (Fig. 12C, arrows indicate 10-nm gold particles),
whereas DRP-1 appeared clustered in the budding regions of
mitochondria in Gal-1-treated cells (Fig. 12D).
DISCUSSION
It is well known that a wide variety of biological and chem-
ical agents, including Gal-1, can induce apoptosis of activated T
lymphocytes (1, 17, 18). However, resting T cells are generally
resistant to apoptotic stimuli (16, 18), and the molecular basis
of this resistance still remains to be elucidated. The role of
phenotypic features of activated T cells, including the expres-
sion of surface activation markers, such as CD69, major histo-
compatibility complex class II or CD38, the increased expres-
sion of CD95/Fas, as well as changes in MMP (i.e. a
hyperpolarization state) have been considered as potential
mechanisms implicated in the generation of susceptibility to
cell death (32, 38). In the present work we demonstrate that
Gal-1 not only bolsters CD95/Fas-mediated cell death but also
induces per se cell death of resting lymphocytes. The mecha-
nisms potentially involved in this effect might include: (i) a
direct interaction of Gal-1 with CD95/Fas receptors; (ii) the
up-regulation of CD95/Fas cell surface expression in resting T
cells; and (iii) changes of MMP, i.e. hyperpolarization, in rest-
ing T cells.
Regarding the first mechanism, we found that anti-Fas neu-
tralizing antibodies (ZB4 clone) were able to inhibit Gal-1-
induced cell death. Accordingly, the apoptotic cascade triggered
by Gal-1 involved the activation of caspase-8. These results
suggest that Gal-1 induces the typical type I cell death path-
way. This apparently conflicts with recent literature data in
which Gal-1 was shown to promote apoptosis in stabilized
lymphoblastoid cell lines via a caspase-independent pathway
(39) or to induce phosphatidylserine exposure without inducing
cell apoptosis (40). However, this discrepancy might depend on
the different Gal-1 concentrations we used and/or, more impor-
tantly, on different experimental systems considered (freshly
isolated lymphocytes versus tumor cell lines). It is, in fact, well
known that the metabolism of tumor cells, in particular lym-
phoblastoid cells, mainly anaerobic, significantly differs from
that of freshly isolated lymphocytes. Accordingly, lymphoblas-
toid cell lines are not responsive to apoptosis-modulating
drugs, e.g. to human immunodeficiency virus protease inhibi-
tors, which are instead very effective both in vivo as well as in
vitro, i.e. on freshly isolated lymphocytes (31). Hence, on the
basis of the previously hypothesized immunoregulatory role
exerted in vivo by Gal-1 (6, 14), the present study was focused
on understanding the mechanisms involved in Gal-1-induced
cell death in a physiological model system, i.e. freshly isolated
human T cells. In fact, during the past few years Gal-1 has been
shown to act as a negative immune regulator under physio-
pathological situations including autoimmunity (6, 8), cancer
(14, 41, 42), and infection (42–44). The observations presented
in this study provide a molecular basis for the immunoregula-
tory properties of this protein.
As regards resting T lymphocytes, important modifications
of these cells seem to be induced by the administration of Gal-1,
e.g. increased CD95/Fas expression and mitochondrial morpho-
genetic changes. No changes either in the expression of cell
surface activation markers or in cell cycle progression and
intracellular redox balance were detected. Hence, the ability of
Gal-1 to induce significant apoptosis of resting cells seems to be
associated with partial mimicking of activation-induced cell
death, at least in terms of Gal-1-induced Fas overexpression
and mitochondrial predisposition to apoptosis, i.e. increased
MMP. A characteristic increase of  (hyperpolarization) as
well as changes in mitochondrial ionic homeostasis have in fact
been detected in different cell types as earlier signs of increased
apoptotic proneness (32, 45–47). In this context, our data indi-
cate that the increase in MMP generated by Gal-1 might rep-
resent a critical event in bolstering cell death. A parallel event
FIG. 12. Immunogold labeling of mitochondrial fission-related
molecules in Gal-1-treated resting T cells. The analysis of the
distribution of 10 nm gold particles revealed that after Gal-1 treatment,
the apoptogenic factors endo G (A) and Cyt c (B) are detectable either on
mitochondrial membranes, including the budding regions, or in the cell
cytoplasm (arrows). Immunogold labeling also revealed the presence of
h-Fis molecules on the mitochondrial membranes, including the bud-
ding region (C, arrows). Conversely, DRP-1 appeared clustered in the
budding region of mitochondria (D, arrows).
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related to the influence of Gal-1 on mitochondrial homeostasis
is represented by the redistribution of these organelles that
migrate to one pole of the cells. This effect was followed by a
massive mitochondrial coalescence, the formation of budding
regions on mitochondria, and, apparently, by fission processes,
late mitochondrial alterations known to be associated with cell
death execution and  loss (45, 46, 48).
The role of mitochondrial fission and fusion processes has
recently been taken into consideration in the context of pro-
grammed cell death (20). It has been hypothesized that an
imbalance in favor of the mitochondrial fission process may
occur in cells undergoing apoptosis, although the fusion process
was reported to be associated with cell senescence and survival.
It has also been suggested that dissipation of MMP might shift
mitochondria toward fragmentation (36), thus contributing to
apoptotic cell death. Fusion and fission processes are in-
structed by a series of molecules, including DRP-1 and h-Fis
(20). The first is a GTPase from the dynamin family, which was
hypothesized to be localized mainly to the outer mitochondrial
membrane. The second was described as an integral protein of
the outer mitochondrial membrane able to recruit DRP-1 to the
fission foci participating in the membrane scission events.
However, little is known to date about the precise role of these
two molecules in physiological systems of programmed cell
death (20, 35). For instance, some data have been obtained by
studying dominant-negative mutants of DRP-1. In this exper-
imental system, the mitochondrial fission process was blocked
and resulted in the inhibition of apoptosis (20). In the same
vein, it has been suggested that DRP-1 could modulate tumor
cell susceptibility to cell death and contribute to the execution
of the apoptotic cascade (20, 35). In our experimental system,
i.e. freshly isolated human resting T lymphocytes, the induc-
tion of mitochondrial remodeling appeared to be associated
with a transient but significant increase of h-Fis expression. By
contrast, Gal-1 treatment did not induce any quantitative
change in DRP-1 expression. However, a redistribution of
DRP-1, which was concentrated in the budding regions of mi-
tochondria, was clearly observed. This is the first demonstra-
tion that DRP-1 could effectively be recruited to participate in
the mitochondrial fission events. Furthermore, in Gal-1-in-
duced cell death of human T lymphocytes mitochondrial mor-
phogenetic changes precede other signs of apoptosis, e.g. nu-
clear chromatin condensation and fragmentation. This seems
thus to represent a suitable physiological model system to
study the role of mitochondrial remodeling occurring during
cell death.
Members of the sphingomyelin pathway have a profound
influence on the apoptotic cascade, including mitochondrial
changes (49). It has also been hypothesized that ceramide tends
to self-aggregate, and its asymmetrical formation in the mem-
brane, e.g. in lipid rafts, may induce negative membrane cur-
vature, which precedes budding and vesiculation (49). On the
basis of our results, we cannot rule out the possibility that the
increased glycosyltransferase activity caused by Gal-1 treat-
ment might lead to the formation of glycosphingolipid species
as second messengers modulating mitochondrial membrane
structure and dynamics. In light of recent literature data, it can
also be hypothesized that another member of the galectin fam-
ily, Gal-3, may also protect normal, nontransformed lympho-
cytes from Gal-1-induced cell death. Gal-3 has in fact been
shown to protect against Gal-1-induced cell death (39), to pre-
vent mitochondrial damage (50), and to promote resistance to
C2-ceramide-mediated apoptosis (34). Finally, lipid rafts are
mainly composed of sphingolipids and have been demonstrated
to be involved in mitochondria-dependent Fas-induced apo-
ptosis (51) as well as in subcellular activities exerted by galec-
tins, including Gal-1 (4, 50). Hence, on the basis of our findings
using specific inhibitors of the ceramide pathway, which are
also able to block mitochondrial fission process, we propose that
Gal-1 could trigger morphogenetic changes of the mitochondria
via a ceramide-mediated pathway. Recent studies also indicate
that other galectins, such as Gal-2 (52), Gal-3 (34), and Gal-9
(53), can promote T cell apoptosis with distinct profiles of
caspase activation and different intracellular signaling events.
In conclusion, our results, obtained by using nonimmortal-
ized and nonengineered freshly isolated T lymphocytes, indi-
cate that Gal-1 can be an excellent model system to analyze the
intracellular events and the role of the morphogenetic changes
of mitochondria in the apoptotic cascade. Our observations also
suggest that this endogenous lectin might play a relevant role
by bolstering physiological Fas-mediated apoptosis in immune
cells. Therefore, Gal-1-mediated death of T lymphocytes may
contribute to immune cell homeostasis and to a successful
escape of tumors from immune surveillance by hindering T
cell-mediated immune reactivity.
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